Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital

[1]  C. Westbury,et al.  Anticholinergic medications for reducing drooling in children with developmental disability , 2020, Developmental medicine and child neurology.

[2]  R. Speyer,et al.  Prevalence of drooling, swallowing, and feeding problems in cerebral palsy across the lifespan: a systematic review and meta‐analyses , 2019, Developmental medicine and child neurology.

[3]  J. Dohar.  Sialorrhea & aspiration control - A minimally invasive strategy uncomplicated by anticholinergic drug tolerance or tachyphylaxis. , 2019, International journal of pediatric otorhinolaryngology.

[4]  A. Geurts,et al.  Development of the Drooling Infants and Preschoolers Scale (DRIPS) and reference charts for monitoring saliva control in children aged 0-4 years. , 2018, Infant behavior & development.

[5]  J. Parr,et al.  Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability , 2017, Archives of Disease in Childhood.

[6]  C. Mcdermott,et al.  Management of oral secretions in neurological disease , 2018 .

[7]  J. Parr,et al.  The drooling reduction intervention trial (DRI): a single blind trial comparing the efficacy of glycopyrronium and hyoscine on drooling in children with neurodisability , 2014, Trials.

[8]  F. Fuchs,et al.  The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial , 2014, Trials.

[9]  A. A. Lakraj,et al.  Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins , 2013, Toxins.

[10]  A. A. Lakraj,et al.  Hyperhidrosis: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum Toxins , 2013, Toxins.

[11]  Karly P Garnock-jones.  Glycopyrrolate Oral Solution , 2012, Pediatric Drugs.

[12]  D. Reddihough,et al.  Prevalence and predictors of drooling in 7‐ to 14‐year‐old children with cerebral palsy: a population study , 2012, Developmental medicine and child neurology.

[13]  H. Cockerill,et al.  Management of drooling in children , 2010, Archives of Disease in Childhood: Education & Practice Edition.

[14]  P. Diz,et al.  Management of drooling in disabled patients with scopolamine patches. , 2010, British journal of clinical pharmacology.

[15]  Ali H. Alrefai,et al.  Management of Sialorrhea in Children with Cerebral Palsy , 2010 .

[16]  Y. Khader,et al.  Treatment of sialorrhea in children with Cerebral Palsy: A double-blind placebo controlled trial , 2009, Clinical Neurology and Neurosurgery.

[17]  P. D. Dios,et al.  Control of drooling using transdermal scopolamine skin patches. A case report. , 2008 .

[18]  J. Limeres Posse,et al.  Control of drooling using transdermal scopolamine skin patches. A case report. , 2008, Medicina oral, patologia oral y cirugia bucal.

[19]  J. Limbeek,et al.  Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care , 2006, Developmental medicine and child neurology.

[20]  J. Rotteveel,et al.  The Treatment of Posterior Drooling by Botulinum Toxin in a Child with Cerebral Palsy , 2005, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

[21]  J. Limbeek,et al.  Social interaction and self-esteem of children with cerebral palsy after treatment for severe drooling , 2005, European Journal of Pediatrics.

[22]  F. Gabreëls,et al.  Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial , 2004, Pediatrics.

[23]  N. Hockstein,et al.  Sialorrhea: a management challenge. , 2004, American family physician.

[24]  J. Bosma,et al.  Oral-motor skills following sensorimotor therapy in two groups of moderately dysphagic children with cerebral palsy: Aspiration vs nonaspiration , 2004, Dysphagia.

[25]  J. Tahmassebi.  Prevalence of drooling in children with cerebral palsy attending special schools , 2003 .

[26]  M. Curzon,et al.  Prevalence of drooling in children with cerebral palsy attending special schools. , 2003, Developmental medicine and child neurology.

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[28]  D. Lewis,et al.  TRANSDERMAL SCOPOLAMINE FOR REDUCTION OF DROOLING IN DEVELOPMENTALLY DELAYED CHILDREN , 1994, Developmental medicine and child neurology.

[29]  Crysdale Ws,et al.  Evaluation and management of the drooling patient. , 1992 .

[30]  D. Reddihough,et al.  The role of a saliva control clinic in the management of drooling , 1992, Journal of paediatrics and child health.

[31]  D. Finkelstein,et al.  Evaluation and management of the drooling patient. , 1992, The Journal of Otolaryngology.

[32]  Crysdale Ws.  Management options for the drooling patient. , 1989 .

[33]  W. Crysdale.  Management options for the drooling patient. , 1989, Ear, nose, & throat journal.

[34]  N. Thomas-Stonell,et al.  Three treatment approaches and clinical factors in the reduction of drooling , 1988, Dysphagia.

[35]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[36]  C. Gordon,et al.  Effect of Transdermal Scopolamine on Salivation , 1985, Journal of clinical pharmacology.

[37]  Dettman Ce.  Suppression of salivation in wind-instrument players with scopolamine. , 1984 .

[38]  C. E. Dettman.  Suppression of salivation in wind-instrument players with scopolamine. , 1984, The New England journal of medicine.